Top Stories

Almirall to allocate €12.5 million of €16.8 million received from CDTI to phase II clinical trial to treat hidradenitis suppurativa

TOPICS:
Almirall edificio id

Posted By: The Corner 23rd January 2026

Alphavalua/ Divacons | The Spanish biopharmaceutical company received a €16.8 million injection in aid from CDTI Innovación, an agency under the Ministry of Science and Innovation, to boost its R&D projects. The company will allocate most of these funds (€12.5 million) to a phase II clinical trial of a monoclonal antibody designed to treat hidradenitis suppurativa, after successfully completing phase I studies in healthy volunteers during 2025. The rest of the grant will support other lines of research by the company, consolidating its commitment to the treatment of chronic inflammatory skin diseases. Almirall’s shares rose by 1.29% yesterday.

About the Author

The Corner
The Corner has a team of on-the-ground reporters in capital cities ranging from New York to Beijing. Their stories are edited by the teams at the Spanish magazine Consejeros (for members of companies’ boards of directors) and at the stock market news site Consenso Del Mercado (market consensus). They have worked in economics and communication for over 25 years.